Filter posts

The Economist – Biotechnology: Fever Rising

After speaking with several attendees and speakers at last week’s BIO CEO & Investor Conference, the …

Business Roundtable: The Reimbursement Landscape under ACA

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one …

#BIOCEO14: An Optimistic Outlook for 2014

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining …

Fireside Chat with Allergan CEO, David Pyott

Day two of the 16th Annual BIO CEO & Investor Conference​ kicked off with a Fireside Chat featuring one …

Open Communication Helps Reduce Rare Disease Drug Development Risk

One of the most important keys to successful relationships – be it in life or …

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the …

What's New in RNAi Therapeutics?

At the 16th Annual BIO CEO & Investor Conference​, Monday morning’s therapeutic workshop, “Delivering the (RNAi) …

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard …

Biotech Investors, Emerging Companies Bullish On 2014

The 16th BIO CEO & Investor Conference is off to a great start. This event …

Buy Side Investors Bullish Ahead of 2014 BIO CEO & Investor Conference

2013 was a record year for the biotech sector, with the NASDAQ Biotechnology Index hitting …